Lung Cancer Considered Podcast: FDA approval of repotrectinib

Lung Cancer Considered host Dr. Stephen Liu moderates a discussion on the November 15, 2023, US FDA approval of repotrectinib for advanced NSCLC with a ROS1 gene fusion based on the single-arm, multi-cohort TRIDENT-1 trial.

Guests included Jessica Lin, MD, Assistant Professor of Medicine at Harvard Medical School Belinda Termeer Center for Targeted Therapies at Massachusetts General Hospital, and Benjamin Besse, MD, PhD, Director of Clinical Research and Gustave Roussy, Villejuif, France.